Amplia gets nod for new cancer drug trial ahead of US push

The Sydney Morning Herald - Nov 19, 2026

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Read full article

More News

The Morning Herald

The Morning Herald is a fast news provider in the United States since 2005. Fiercely independent and armed with irreverent intelligence, there’s no other place to get your news other than The Morning Herald.

NEWSLETTER